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Abstract
One of the puzzles in cancer predisposition is that
women carrying BRCA-1 mutations preferentially de-
velop tumors in epithelial tissues of the breast and
ovary. Moreover, sporadic breast tumors contain lower
levels of BRCA-1 in the absence of mutations in the
BRCA-1 gene. The problem of tissue specificity re-
quires analysis of factors that are unique to tissues of
the breast. For example, the expression of estrogen
receptor-A (ERA) is inversely correlated with breast
cancer risk, and 90% ofBRCA-1 tumors are negative for
ERA. Here, we show that estrogen stimulates BRCA-1
promoter activity in transfected cells and the recruit-
ment of ERA and its cofactor p300 to an AP-1 site that
binds Jun/Fos transcription factors. The recruitment of
ERA/p300 coincides with accumulation in the S-phase
of the cell cycle and is antagonized by the antiestrogen
tamoxifen. Conversely, we document that overexpres-
sion ofwild-type p53 prevents the recruitment of ERA to
the AP-1 site and represses BRCA-1 promoter activity.
Taken together, our findings support a model in which
an ERA/AP-1 complex modulates BRCA-1 transcription
under conditions of estrogen stimulation. Conversely,
the formation of this transcription complex is abro-
gated in cells overexpressing p53.
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Introduction
The breast and ovarian cancer susceptibility gene BRCA-1
[1,2] encodes for a transcription factor, which contributes to
recombination and DNA repair functions [3–5]. Reduced
levels of wild-type BRCA-1 protein have been detected in a
large percentage of sporadic breast tumors in the absence
of mutations in the BRCA-1 gene [6], suggesting that dis-
ruption of BRCA-1 expression may be a contributing factor
to the onset of mammary carcinogenesis [7]. Exposure to
ovarian estrogens has been recognized as one risk factor in
breast tumorigenesis based on the evidence that therapies with
the estrogen receptor agonist tamoxifen (TMX) reduced the
incidence of breast cancer [8]. Effects of estrogen on respon-
sive genes are mediated by two estrogen receptors: estrogen
receptor-a (ERa) and estrogen receptor-b (ERb). In the classic
pathway, ERa contacts the DNA at specific estrogen-respon-
sive elements (EREs) comprising target genes and recruits
coactivators and cofactors that enhance transcription [9]. Al-
ternatively, ERa may physically interact with p160/p300 pro-
teins bound to an AP-1 (Jun/Fos) complex that contacts DNA
[10]. The profile of cofactors and the type of ligand have been
shown to influence the transcription activity of ERa [11,12].
The expression of BRCA-1 peaks in the S-phase of the cell
cycle [13–15] and is induced by estrogen in breast cancer cell
lines [16,17] and estrogen plus progesterone in the mammary
gland of ovariectomized mice [18]. Although estrogen depletion
reduces BRCA-1 expression [19], the stimulatory effects of
estrogen on BRCA-1 expression are believed to be indirect
based on the observations that the proximal BRCA-1 promoter
lacks consensus EREs that bind ERa and that de novo protein
synthesis is required for BRCA-1 upregulation [20]. To clarify
the mechanisms of estrogen stimulation of BRCA-1 expression,
we investigated whether estrogen regulated BRCA-1 transcrip-
tion through an alternative pathway involving the recruitment of
complexes containing ERa at non-EREs in the BRCA-1 pro-
moter. We report that, in response to estrogen, an ERa/p300
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complex is recruited to an AP-1 domain located in the proxi-
mal BRCA-1 promoter and activates BRCA-1 transcription,
whereas the overexpression of p53 prevents the recruitment
of ERa and represses BRCA-1 promoter activity.
Materials and Methods
Cells, Transient Transfections, and Luciferase Assay
HCT116 and HCT116 p53KO cells were a generous gift
from B. Vogelstein. MCF-7 and HeLa cells were obtained
from the American Type Culture Collection (Rockville, MD).
The plasmid pTam67 was originated by cloning the Tam67
cDNA into the EcoRI site of pCR3.1. Transient transfections
were performed using the Lipofectamine-Plus procedure
according to the manufacturer’s instructions (Life Technolo-
gies, Inc., Carlsbad, CA). Briefly, 24 hours after cells were
plated, each well was cotransfected with the appropriate
plasmid and an internal control plasmid pRL-TK (renilla lucif-
erase gene). Cells were incubated with the DNA–liposome
complex for 3 hours at 37jC in 5% CO2. Following transfec-
tion, cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) plus 5% charcoal-stripped fetal bovine
serum (FBS) and allowed to recover for 48 hours. Cells were
then treated in DMEM containing either control (ethanol ve-
hicle) or 10 nM 17b-estradiol (E2) for the times indicated.
Western Blot Analysis and Flow Cytometry
Western blot analysis for BRCA-1 was performed as
described previously [21]. Cell extracts were normalized to
protein content and separated by 4% to 12% gradient sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Immunoblotting was carried out with antibodies
raised against BRCA-1 (Ab-2; Oncogene Research Prod-
ucts, Cambridge, MA). Normalization of Western blots was
confirmed by incubating immunoblots with b-actin antibody-1
(Oncogene Research Products). The immunocomplexes
were detected by enhanced chemiluminescence (Amersham
Corp., Arlington Heights, IL). Flow cytometry was performed
in triplicate as described previously [22]. Briefly, cells were
harvested with trypsin and washed in phosphate-buffered
saline (PBS). Then cells were treated with RNAse and
stained with propidium iodide (70 mM in PBS). Cell cycle
distribution profiles were recorded with a FACscan (Becton
Dickinson, San Jose, CA), using a CELLQuest program.
Electrophoretic Mobility Shift Assay (EMSA)
Cells were plated in DMEM plus 5% charcoal-stripped
FBS. After 24 hours, cells were treated for 24 hours with
10 nM E2 then subsequently harvested. Briefly, cells were
trypsinized then washed with ice-cold DPBS. Cells were
resuspended in ice-cold 25 mM Hepes buffer containing
1.5 mM EDTA, 1 mM DTT, 0.5 mM PMSF, and 5 mg/ml
aprotinin, and placed on ice for 10 minutes. Cells were
pelleted and resuspended in 1 ml of ice-cold 25 mM Hepes
buffer containing 1.5 mMEDTA, 10% (vol/vol) glycerol, 1 mM
DTT, 0.5 mM PMSF, and 5 mg/ml aprotinin. The cell suspen-
sion was transferred to a mortar for drilling with a Teflon
pestle until more than 90% of the cells in a 2-ml aliquot were
unable to exclude trypan blue. After centrifugation, cell
pellets were resuspended in 150 ml of ice-cold 25 mM Hepes
buffer containing 1.5 mMEDTA, 10% (vol/vol) glycerol, 0.5 M
KCl, 1 mM DTT, 0.5 mM PMSF, and 5 mg/ml aprotinin, and
placed on ice with intermittent vortexing. Cell debris was
removed by centrifugation. Supernatants containing nuclear
protein were stored at 70jC. Nuclear protein concentra-
tion was determined using the BCA protein assay (Pierce
Chemical Company, Rockford, IL). Oligonucleotides used
for binding and gel retardation assay were: BRCA-1, 5V-
AACCTGAGAGGCGTAAGGCGTT-3V (sense) and 5V-
AACGCCTTACGCCTCTCAGGTT-3V (antisense); and
consensus TRE, 5V-CAAACACATGAGTAATGTGTT-3V
(sense) and 5V-AACACATTACTCATGTGTTTG-3V from the
human collagenase promoter. The complementary oligonu-
cleotides were annealed then phosphorylated at the 5V-end
with [g-32P]ATP and T4 polynucleotide kinase. Unincorpo-
rated nucleotides were removed using the TE-10 spin col-
umns (Clontech, Mountain View, CA). Binding assays were
performed by incubating 5 mg of nuclear protein in the binding
buffer then incubated with the labeled oligonucleotides for
20 minutes. For supershift assays, antibodies (Affinity Biore-
agents, Boulder, CO) were incubated with 1-mg nuclear
extracts for 2 hours prior to addition of labeled oligonucleo-
tides. For cold competition, a 100-fold excess of the respec-
tive unlabeled oligonucleotides was added to the binding
reaction 10 minutes prior to addition of the labeled oligo-
nucleotides. Samples were electrophoresed through a 5%
nondenaturing polyacrylamide gel at 200 V for 90 minutes.
Finally, the gel was dried and exposed to a phosphor screen,
and digital phosphorimages were retrieved using the Storm
system (Molecular Dynamics, Piscataway, NJ).
Chromatin Immunoprecipitation (ChIP) Assay
Cells were collected after fixation of protein and DNA
through the addition of formaldehyde for a final concentration
of 1% to the cell culture medium and incubated at 25jC for
10 minutes. Prior to collection, cells were washed twice in cold
DPBS. The cells were resuspended in a lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris–HCl, and protease inhibitor
cocktail). After sonication, the dilution of chromatin prepara-
tions was either reserved as input (no antibody) material or
utilized for immunoprecipitation with the desired antibody.
After immunoprecipitation, DNA was recovered and subjected
to polymerase chain reaction (PCR) analysis using the follow-
ing primers: BRCA-1, forward: ATCGGTACCAAGTGATGC
TCTGGGGTACTG, reverse: ACTAGATCTACCTCATGAC-
CAGCCGACGTT (237 bp), flanking the AP1-binding site. As
a positive control for estrogen treatment and ChIP assay for
ERa, we tested for the recruitment of ERa at the ERE region
of the estrogen-inducible pS2 gene using the primers: for-
ward: TATGAATCACTTCTGGAGTGA; reverse: GAGCGT-
TAGATAACATTTGCC (289 bp). As negative controls, we
tested for the recruitment of ERa at exon 7 of the BRCA-1
gene using forward: 5V-ATGCAAACAGCTATAATTTTG-3V;
reverse, 5V-CAAGGAAGGATTTTCGGGTTC-3V (140 bp) and
through coincubation with IgG.
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Results
Estrogen Induces BRCA-1 Promoter Activity
In transient transfection assays with ERa-positive MCF-7
breast cancer cells, we found that the treatment with E2 for
24 hours, but not in earlier time points (data not shown), stim-
ulated by a factor of 2.0 the transcriptional activity of a 1.69-kb
BRCA-1 promoter–reporter construct (pGL3BRCA-1) [21]
containing both transcription start sites for exons 1A and 1B
(Figure 1A). The E2 treatment stimulated luciferase reporter
activity from a positive control promoter–reporter construct
(p3XERE) containing an array of three consensus EREs
(Figure 1B) and the accumulation of BRCA-1 protein
(Figure 1C). The requirement for ERa in the E2-dependent
regulation of BRCA-1 transcription was confirmed in cervical
HeLa and colon HCT116 cancer cells transiently transfected
with pGL3BRCA-1 plus a vector encoding for ERa (pERa).
For these experiments, we adopted transfection conditions
similar to those of previous studies, which examined the role
of BRCA-1 on ERa signaling [23]. In detail, we transfected
f70% confluent 24-well dishes with 0.5 mg of pERa. Our re-
sults indicated that in ERa-negative HeLa (Figure 1D) and
HCT116 (Figure1E ) cells transfectedwitheither pGL3BRCA-
1 or an empty vector (pCR3.1), E2 treatment was not suffi-
cient to induce BRCA-1 promoter activity. However, BRCA-1
transcription became responsive to E2 following cotransfec-
tion with various amounts of pERa as documented by stim-
ulation of luciferase activity from pGL3BRCA-1. Similarly,
transcription from the positive control p3XERE reporter con-
struct was induced by E2 on cotransfection with pERa. The
cotransfection of ERa into HeLa and HCT116 cells produced
a fold induction in BRCA-1 transcription, similar to that ob-
served in transfected MCF-7 cells expressing endogenous
ERa and treated with E2.
In search of non-ERE sites located in the proximal BRCA-1
promoter that may recruit transcription complexes containing
ERa, we mapped a sequence (5V-CTGAG-3V) with significant
homology to consensus sequences for AP-1 transcription
factors [24] at positions 27/31 upstream of the transcrip-
tion start site on exon 1B (Figure 2A). Site-directed muta-
genesis of the candidate AP-1–like (CTGAG to CACTA) site
abrogated basal and E2-dependent activity of the BRCA-1
promoter, as evidenced by the significant reduction in lucifer-
ase activity observed in MCF-7 cells transfected with a
mutated BRCA-1 promoter– luciferase reporter construct
(pAP1mut) (Figure 2B). Moreover, cotransfection with an
expression vector encoding for a dominant-negative variant
(pTam67) of c-Jun abrogated basal and E2-induced BRCA-1
promoter activity (Figure 2C), confirming the requirement
for AP-1 in basal and estrogen-dependent regulation of
BRCA-1 transcription.
Estrogen Stimulates the Recruitment of ERa to an AP-1
Site in the BRCA-1 Promoter Region
We used ChIP assays to investigate whether or not estro-
genstimulated the recruitment ofERa to theBRCA-1promoter
region containing the AP-1 domain. Based on the information
that BRCA-1 levels peak in S-phase [25], we enriched the
fraction of MCF-7 cells positioned in the G1 phase of the
cell cycle (Table 1). Time course experiments showed that
E2 stimulated the recruitment of ERa to a BRCA-1 promoter
fragment comprising the AP-1–like motif (Figure 3A). This
was accompanied by recruitment of p300 (Figure 3B) and
accumulation of cells in S-phase (71.5%) (Table 1). Con-
versely, the E2-induced accumulation in S-phase and the
recruitment of ERa and p300 were antagonized by cotreat-
ment with TMX (Figure 3C). Even though the treatment
with TMX was stimulated by f50% BRCA-1 promoter ac-
tivity, in combination with E2, it antagonized the activation
of BRCA-1 transcription. These agonist/antagonist effects
of TMX were similar to those exerted by this compound on
the expression of other estrogen-responsive genes [10].
The E2 treatment stimulated the recruitment of c-Jun and
FosB (Figure 3D), confirming that AP-1 contributed to the
formation of a transcription complex at this region. Control
experiments indicated that the coincubation of cross-linked
chromatin with preimmune IgG did not generate a corre-
sponding BRCA-1 amplification product (Figure 3E ). Neither
did E2 stimulate the recruitment of ERa to the coding region
of exon 7 in the BRCA-1 gene (Figure 3F ). However, the
treatment with E2 triggered the recruitment of ERa to an
ERE in the pS2 gene (Figure 3G), thus confirming the effi-
cacy of the E2 treatment and the experimental conditions
for the ChIP assay.
To obtain additional evidence that the BRCA-1 promoter
region containing the AP-1 site was targeted for binding
by ERa, we incubated nuclear extracts obtained from E2-
treated MCF-7 cells with a BRCA-1 oligonucleotide spanning
22 bp (40/19) upstream of the exon 1B transcription start
site. The incubation of nuclear extracts with the BRCA-1
oligonucleotide produced two distinct complexes (bands A
and B). Band A was supershifted in a dose-dependent
fashion following coincubation of theBRCA-1 oligonucleotide
with increasing amounts of an ERa antibody (ERaAb)
(Figure 3H ), suggesting that this complex contained ERa.
These results mapped the binding region for ERa to the
BRCA-1 promoter segment comprised between 40 and
19 bp, which included the AP-1–like domain. Conversely,
the coincubation of nuclear extracts with control preimmune
IgG did not produce a supershifted band. The formation of
complex A was competed by coincubation with excess cold
oligonucleotide containing the consensus AP-1 sequence 5V-
TGACTCA-3V from the human collagenase promoter (data
not shown), confirming that the BRCA-1 oligonucleotide was
a target for AP-1. Taken together, these results suggested
that induction of BRCA-1 transcription by estrogen required
the concomitant expression of ERa and its occupancy along
with p300 at an AP-1 site in the proximal BRCA-1 promoter.
Overexpression of p53 Prevents the Recruitment of ERa
to AP-1 and Represses BRCA-1 Transcription
In previous studies, p53 has been shown to repressBRCA-
1 expression [21,26], through yet unknown mechanisms.
Therefore, we examined whether or not p53 interfered with
E2 stimulation of BRCA-1 transcription. In transient transfec-
tion experiments with MCF-7 cells, we found that basal and
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E2-induced BRCA-1 promoter activities were repressed
following cotransfection with various amounts of a vector en-
coding for wild-type p53 (p53WT) (Figure 4A). In parallel
transfection experiments with HCT116 cells lacking p53
(HCTKO, p53/), the treatment with E2 did not influence
BRCA-1 transcription in cells cotransfected with pGL3BRCA-1
plus the empty vector pCMV (Figure 4B). The cotransfection
with pGL3BRCA-1 plus pERa did not alter basal promoter
activity, but resulted in a modest increase (f20%) in BRCA-1
transcription following E2 treatment. Conversely, the cotrans-
fection of HCTKO cells with various amounts of p53WT re-
pressed BRCA-1 promoter activity in a dose-dependent
fashion. However, the relative induction by E2 was greater in
cells transfected with higher amounts (0.25–1.0 mg) of p53WT,
suggesting that E2 regulation of BRCA-1 transcription was
influenced by the relative expression levels of p53 and ERa.
Based on the information that p53 physically interacts
with ERa [27], we asked whether or not overexpression of
p53 modulated the recruitment of ERa to the AP-1 site. ChIP
experiments with MCF-7 cells indicated that E2-induced
recruitment of ERa to this site was repressed following
overexpression of exogenous p53WT (Figure 5, A and B).
These findings suggested that p53 represses E2-induced
BRCA-1 transcription by preventing the recruitment of ERa
to the BRCA-1 promoter. Western blot analysis confirmed
that in MCF-7 cells overexpressing p53, the induction of
BRCA-1 protein by E2 was greatly reduced compared with
MCF-7 cells transfected with the empty plasmid pCMV.
These data suggested that the interaction of ERa at the
AP-1 was critical for the E2-dependent increase in BRCA-1
protein observed in Western blots.
Discussion
The objective of the present study was to investigate whether
or not E2 activated BRCA-1 promoter activity and the poten-
tial involvement of ERa. Previous studies have documented
that E2 stimulates BRCA-1 expression [16,17]. However, the
lack of EREs in the promoter of BRCA-1 has led to the
suggestion that E2 activation of BRCA-1 expression is indi-
rect [20]. In this study, we used a 1.7-kb BRCA-1 promoter
fragment containing both transcriptional start sites of exons
1A and 1B [21] to investigate the E2 regulation of the BRCA-1
promoter. The results of transfection studies indicated that
E2 stimulated BRCA-1 promoter–reporter activity in breast
MCF-7 cells expressing endogenous ERa, and in colon
(HCT116) and cervical (HeLa) cells cotransfected with a
plasmid encoding for ERa. Our transfection conditions were
similar to those used in previous studies, which examined the
interplay between BRCA-1 and ERa [23]. In the current
study, the efficacy of transfection conditions and E2 treat-
ment was confirmed by induction in transfected cells of
transcription activity from a control expression construct
containing an array of three consensus EREs (p3XERE),
as well as accumulation of BRCA-1 protein in MCF-7 cells.
Conversely, cotreatment with the antiestrogen TMX abro-
gated E2-induced BRCA-1 promoter activity in MCF-7 cells,
confirming the involvement of ERa in the regulation of
BRCA-1 transcription.
The action of ERa at an ERE (5V-GGTCAnnnTGACC-3V)
is well understood and involves the direct binding of ER
homodimer to DNA and the recruitment of coactivators
including CBP/p300 and p160 [9,28]. Alternatively, ERa
has been shown to activate the transcription of several E2-
inducible genes including IGF-1 [29], collagenase [30], and
cyclin D [31] at AP-1 sequences that bind members of the
Jun and Fos families. Inspection of the proximal BRCA-1
promoter revealed its presence in close proximity to the exon
1B transcription start site of an element (CTGAG) homolo-
gous to a sequence that binds AP-1 factors [24]. Several
observations presented in this report support the notion that
this site is important for basal and E2-induced regulation of
BRCA-1 transcription. First, mutation of the candidate AP-1
site, as well as overexpression of a dominant-negative vari-
ant of c-Jun (pTam67), led to repression of BRCA-1 pro-
moter activity in transfected MCF-7 cells. These results were
in agreement with those of previous investigations docu-
menting that mutation of sites binding Jun/Fos proteins and
expression of Tam67 reduced basal and E2-inducible AP-1
transactivation [32–34]. Second, the results of ChIP assays
provided direct evidence that the BRCA-1 promoter region
flanking the AP-1 site was targeted by c-Jun and FosB in the
treatment of MCF-7 cells with E2. Compared to other mem-
bers of the Jun and Fos families, c-Jun and FosB are con-
sidered strong transactivators [35], and their recruitment to
the BRCA-1 gene highlights the role of AP-1 in E2-dependent
activation of BRCA-1 transcription. Third, treatment with E2
induced the recruitment of ERa and its cofactor p300 to the
BRCA-1 promoter region comprising the AP-1, whereas the
antiestrogen TMX antagonized these effects. Results of
EMSAs mapped the recruitment of ERa to a 21-bp promoter
region (40 and 19 bp) spanning the AP-1 site. These
cumulative data are consistent with a model that attributes to
ERa and its coactivator p300 a key role in the activation of
BRCA-1 transcription through an AP-1. The physiological
relevance of these findings is that ERa/AP-1 interactions
may lead to activation of BRCA-1 promoter activity, which
is paralleled by an increase in BRCA-1 protein. Unlike gel
Figure 1. Estrogen induces BRCA-1 promoter activity in transiently transfected MCF-7 cells. (A) MCF-7 cells were precultured for 4 days in phenol red– free
DMEM containing 5% charcoal dextran–stripped FBS (Hyclone Laboratories, Logan, UT). Then, a 1.69-kb fragment of the BRCA-1 5 V flanking region driving the
expression of a luciferase cassette (pGL3BRCA-1) was transiently transfected, using Lipofectamine Plus (Life Technologies, Inc.), into MCF-7 cells, which were
cultured in DMEM or DMEM plus 10 nM E2 (Sigma, St. Louis, MO) for various periods of time. (B) The treatment with E2 induces promoter activity from a positive
control vector (p3XERE) transfected into MCF-7 cells. (C) Western blot analysis with antibodies for BRCA-1 (Ab-2) and -actin (Ab-1) (Oncogene Research
Products) documents that BRCA-1 protein levels are induced in MCF-7 cells cultured for 24 hours in DMEM plus 10 nM E2. (D) HeLa and (E) HCT116 cancer cells
were cotransfected with pGL3BRCA-1 and either a plasmid encoding for ERa (pERa) or an empty vector (pCR3.1). Transfected cells were cultured in DMEM or
DMEM plus 10 nM E2 for 24 hours. Control plates were transfected with p3XERE. Bars represent mean luciferase units corrected for the internal control renilla ±SE
from two independent experiments performed in quadruplicate.
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mobility studies with segments of the BRCA-1 promoter, the
ChIP assay offered the opportunity to examine the re-
cruitment of these transcription factors to the BRCA-1 pro-
moter in the context of the native chromatin.
The dynamics of cofactor recruitment to the AP-1 site is
likely complex and involves an orderly recruitment of tran-
scription factors and alterations in chromatin state [9]. For
example, the participation of p300, which possesses intrinsic
histone acetyl transferase (HAT) activity [36], in the forma-
tion of the transcription complex recruited at the AP-1 may be
a key event that may lead to chromatin remodeling and
activation of BRCA-1 transcription. This notion is supported
by the current observations that cotreatment with TMX
antagonized the recruitment of p300 to the AP-1 site and
antagonized the stimulatory effects of E2 on BRCA-1 pro-
moter activity. In this study, although we did not assess the
presence of p160s, members of this family of transcription
factors have been shown to physically interact with ERa at
AP-1 sites [28]. One possibility is that Jun/Fos heterodimers
bound to the BRCA-1 DNA may recruit p300–p160s, where-
as ERa may be recruited to the complex through contacts
with the coactivator p160 [37]. Furthermore, it is plausible
that ERa may form bridges with accessible transcription
Figure 2. An AP-1– like site contributes to estrogen-induced BRCA-1 promoter activity. (A) Position of the candidate AP-1 element in the BRCA-1 promoter. (B)
MCF-7 cells were precultured for 4 days in DMEM with 5% FBS and then transiently transfected with pGL3BRCA-1 or pGL3BRCA-1 mutated at the AP-1 site
(pAP1mut). p3XERE is a positive control for treatment with 10 nM E2. (C) Transient transfection of MCF-7 cells with a dominant-negative c-Jun plasmid (pTam67)
represses basal and estrogen-regulated BRCA-1 transcription. (B and C) Data represent mean luciferase units corrected for the internal control renilla ±SE from
two independent experiments performed in quadruplicate.
Table 1. Estrogen Stimulates G1-Phase to S-Phase Transition of MCF-7
Cells.
Treatment G1 S G2/M
4 days in DMEM 65.0 34.5 0.5
After 24 hr in DMEM 40.5 59.0 0.5
E2 28.0 71.5 0.5
TMX 54.6 42.0 3.4
TMX + E2 35.2 61.2 3.6
MCF-7 cells were precultured for 4 days in phenol red– free DMEM con-
taining 5% charcoal dextran–stripped FBS. Then cells were cultured for
24 hours in basal DMEM or DMEM supplemented with 10 nM E2, 1 AM TMX,
or their combination. Cell were stained with propidium iodide and used for
flow cytometry. Cell cycle distribution profiles were recorded with a FACscan
(Becton Dickinson) using a CELLQuest program.
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factors recruited at adjacent sites in the BRCA-1 promoter.
For example, we identified just upstream of the AP-1 site a
consensus sequence (5V-GGGCGG-3V) for the transcription
factor Sp1, which has been shown to interact with ERa [38].
This potential interaction may stabilize the ERa/p300 tran-
scription complex formed at the AP-1. Finally, another factor
that may influence the degree and temporal activation of the
BRCA-1 gene by E2 is the relative abundance and profile of
AP-1 proteins recruited to the BRCA-1 promoter. Regardless
of the precise complement of cofactors and coactivators
recruited at the AP-1 site, our studies showed that ERa
and p300 play an important role in E2-dependent activation
of the BRCA-1 promoter. The recruitment of an ERa/p300
complex to an AP-1 rather than an ERE site may integrate
the role of AP-1 in the regulation of cell proliferation [37] with
that of BRCA-1 in cell growth response. The fact that the
Figure 3. Treatment of MCF-7 cells with estrogen stimulates BRCA-1 promoter occupancy by ERa and p300 to an AP-1 site. (A) MCF-7 cells were precultured for
4 days in DMEM with 5% FBS and then treated with 10 nM E2 for various periods of time. Cells were processed for ChIP assay using an antibody against ERa
(Neomarkers, Fremont, CA). Inputs are control bands generated by PCR from cross-linked chromatin. (B) At 24 hours, estrogen stimulates the recruitment of ERa
and p300 (antibody from Affinity Bioreagents), whereas 1 M TMX (Sigma) antagonizes E2-dependent recruitment of ERa and p300. (C) E2-induced BRCA-1
transcription in transiently transfected MCF-7 cells is antagonized by cotreatment with TMX. (D) E2 stimulates the recruitment of c-Jun and FosB. (E) Coincubation
with IgG followed by PCR amplification does not produce a band comprising the AP-1 segment. (F) The recruitment of ERa to a region of exon 7 in the BRCA-1
gene (negative control) is not stimulated by E2, which stimulates (G) the recruitment of ERa to an ERE in the pS2 gene (positive control). The size of the amplicon
was 237 bp for BRCA-1 (98 to +139 bp from +1 on exon 1B), 289 bp for the pS2 ERE, and 140 bp for exon 7 of the BRCA-1 gene. (H) EMSA for ERa at the
BRCA-1 promoter. MCF-7 cells were precultured for 4 days in DMEM with 5% FBS and then treated for 24 hours with E2. Nuclear extracts were coincubated with a
32P-labeled BRCA-1 oligonucleotide (40/19 bp) plus various amounts of mouse IgG or an antibody for ERa. The ERa antibody supershifted a complex (band A)
in a dose-dependent manner, thus confirming the presence of ERa at this region; FP, free probe.
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kinetics and magnitude of BRCA-1 induction by E2 are dif-
ferent from those of inducible genes containing EREs [20]
may be due to the type of transcriptional response that is
required for BRCA-1. Elevation of BRCA-1 expression as
cells enter S-phase may offer a control mechanism that
activates DNA repair and cell cycle checkpoints before
DNA replication occurs [14].
Previous studies by other investigators [39,40] and our
laboratory [21] documented that BRCA-1 expression levels
were downregulated in response to p53 induction and that
these effects were due to transcriptional repression by p53.
However, no consensus p53-binding sites have been found
in the BRCA-1 promoter [39], suggesting that the repressive
effects of p53 on BRCA-1 transcription are not mediated
through direct binding to target DNA sequences. In this
study, we found that overexpression of p53 counteracted
the E2-dependent upregulation of BRCA-1 promoter activity.
Results of ChIP assays documented that the recruitment of
ERa to the AP-1 site in the BRCA-1 promoter was abrogated
in MCF-7 cells overexpressing exogenous p53. One poten-
tial explanation for these results is that p53 may physically
interact with ERa, thus hampering the transcriptional activity
of the liganded ERa [27]. The interaction between p53 and
ERa occurs at multiple sites on the ERa protein and inter-
feres with the ability of ERa to bind to EREs or other proteins
in an ERa-mediated transcription complex [41]. In addition,
p53 may interfere with the recruitment of p300 and factors
associated with AP-1, while stimulating the recruitment of
corepressors and histone deacetylases. For example, the
physical interaction of p53 with histone deacetylase-1 and
mSin3a has been reported to mediate transcriptional repres-
sion of the Map4 gene [42]. Other reports documented that
p53 binds to p300 in a region that is required for its intrinsic
HAT activity [36]. The formation of p53–p300 complexes has
been shown to reduce the amount of p300 available and
repress transcription from an AP-1 site, whose activation is
p300-dependent [43].
Overall, these findings provided evidence for a direct role
of ERa in the regulation of BRCA-1 promoter activity by E2.
The increased expression of BRCA-1 may lead to activa-
tion of S-phase checkpoints, including p53 and p21 [40,44–
46] and DNA damage-responsive genes [47] (Figure 5).
This signaling may be of particular significance in cells of
the breast, which undergo cyclic proliferative pressure by
Figure 3. (continued)
Figure 4. Overexpression of wild-type p53 represses basal and estrogen-
induced BRCA-1 transcription. (A) MCF-7 and (B) HCTKO (p53/) cells
were precultured for 4 days in DMEM with 5% FBS and then transiently
transfected with pGL3BRCA-1 or pGL3BRCA-1 plus various amounts of a
plasmid encoding for wild-type p53 (p53WT) (gift from Bert Vogelstein, John
Hopkins University, Baltimore, MD) under the control of the cytomegalovirus
(CMV) promoter or an empty plasmid (pCMV). Where indicated, the HCTKO
cells were cotransfected with 3.0 g of pERa. Transfected cells were cultured
in DMEM or DMEM supplemented with 10 nM E2 for 24 hours. Bars represent
mean luciferase units corrected for the internal control renilla ±SE from two
independent experiments performed in quadruplicate.
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ovarian estrogens. Without the positive regulation of BRCA-1
expression by ERa, it is conceivable that E2 may stimulate
progression through S-phase without proper control, and in-
crease the risk for cancer growth in E2-responsive tissues.
Studies have shown that 90% of BRCA-1 tumors are likely
to be ER-negative [48] and may explain the lower levels of
BRCA-1 observed in sporadic breast tumors [6]. In turn, in-
creased expression of BRCA-1may inhibit the transcriptional
activity of ERa as suggested by earlier studies [23].
Our results also indicated that endogenous p53 levels ap-
peared to have no effects of ERa recruitment on the BRCA-1
promoter. Conversely, overexpression of p53 antagonized the
recruitment of ERa to the AP-1 site. These data may explain,
at least in part, how accumulation of p53 leads to repression
of BRCA-1 transcription [39]. Interestingly, upregulation of
BRCA-1 has been shown to stabilize wild-type p53, providing
a feedback loop in which these tumor-suppressor genes re-
gulate each other [26]. Overall, the interplay between the
positive regulation and the negative regulation by ERa and
p53, respectively, on BRCA-1 expression may be part of an
integral signaling pathway that is mediated by AP-1 and de-
termines whether the cell undergoes checkpoints/DNA
repairs or apoptosis should the damage be irreparable. Dis-
ruption of this trafficking may predispose to the onset of
breast cancer.
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